Ocugen, Inc. (OCGN)
NASDAQ: OCGN · Real-Time Price · USD
1.280
-0.030 (-2.29%)
At close: Aug 5, 2026, 4:00 PM EDT
1.290
+0.010 (0.76%)
After-hours: Aug 5, 2026, 7:59 PM EDT
Ocugen Employees
Ocugen had 116 employees as of December 31, 2025. The number of employees increased by 21 or 22.11% compared to the previous year.
Employees
116
Change (1Y)
21
Growth (1Y)
22.11%
Revenue / Employee
$38,491
Profits / Employee
-$617,871
Market Cap
433.31M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 116 | 21 | 22.11% |
| Dec 31, 2024 | 95 | 30 | 46.15% |
| Dec 31, 2023 | 65 | -19 | -22.62% |
| Dec 31, 2022 | 84 | 28 | 50.00% |
| Dec 31, 2021 | 56 | 41 | 273.33% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Cabaletta Bio | 158 |
| Sutro Biopharma | 133 |
| Editas Medicine | 87 |
| Prelude Therapeutics | 79 |
| Larimar Therapeutics | 71 |
| Prothena Corporation | 67 |
| Eupraxia Pharmaceuticals | 49 |
| Inhibikase Therapeutics | 35 |
OCGN News
- 5 days ago - Ocugen to Participate in Upcoming August Investor Conferences - GlobeNewsWire
- 6 days ago - Ocugen Proxy statement: Proxy filing - Filings
- 6 days ago - Ocugen Proxy statement: Proxy filing - Filings
- 7 days ago - Ocugen granted RMAT designation for OCU410 - TheFly
- 7 days ago - Ocugen Announces that the U.S. Food and Drug Administration Has Granted OCU410 Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Geographic Atrophy, Secondary to Dry Age-Related Macular Degeneration - GlobeNewsWire
- 8 days ago - Ocugen to Host Conference Call on Thursday, August 6 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2026 Financial Results - GlobeNewsWire
- 16 days ago - Ocugen Proxy statement: Proxy filing - Filings
- 23 days ago - Ocugen announces $4M OCU400 license agreement with Roots Pharmaceutical - TheFly